This strategic shift was highlighted by Clear Street analysts, who initiated coverage with a Buy rating and a $20 price target, citing the company's potential for stable growth. Furthermore, Core Scientific appointed KPMG as its new auditor, replacing Marcum LLP, and addressed material weaknesses in its internal controls. H.C. Wainwright maintained a Buy rating with a $17 price target, emphasizing Core Scientific's relationship with CoreWeave, which recently secured a contract with OpenAI and plans an IPO. Compass Point also reaffirmed a Buy rating with a $20 target, noting the company's extended contract with CoreWeave and strong unit economics. These developments underscore Core Scientific's evolving business strategy and financial outlook. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.